Loading...

Cardax, Inc.

CDXIPNK
Healthcare
Biotechnology
$0.001
$0.00(400.00%)

Cardax, Inc. (CDXI) Company Profile & Overview

Explore Cardax, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Cardax, Inc. (CDXI) Company Profile & Overview

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

SectorHealthcare
IndustryBiotechnology
CEOMr. David G. Watumull

Contact Information

808 457 1400
2800 Woodlawn Drive, Honolulu, HI, 96822

Company Facts

10 Employees
IPO DateMar 6, 2013
CountryUS
Actively Trading

Frequently Asked Questions